Next Article in Journal
The Prostate Cancer Rehabilitation Clinic: A Biopsychosocial Clinic for Sexual Dysfunction after Radical Prostatectomy
Previous Article in Journal
Oncology Communities of Practice: Insights from a Qualitative Analysis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 25
Issue 6
10.3747/co.25.4287
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort

by
R.A. Juergens
1,*,
C. Mariano
2,
J. Jolivet
3,
N. Finn
4,
J. Rothenstein
5,
M.N. Reaume
6,
A. Faghih
7,
C. Labbé
8,
S. Owen
9,
F.A. Shepherd
10,
J. Villeneuve
11,
F. Romeyer
11,
F. Pettersson
11 and
C. Butts
12
1
Juravinski Cancer Centre, Hamilton, ON L8V 5C2, Canada
2
Royal Columbian Hospital, New Westminster, BC, Canada
3
Recherche Médicale Saint-Jérôme Inc., Saint-Jérôme, QC, Canada
4
Centre Hospitalier Universitaire Dr-Georges-L.-Dumont, Moncton, NB, Canada
5
R.S. McLaughlin Durham Regional Cancer Centre, Oshawa, ON, Canada
6
The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
7
Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON, Canada
8
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, QC, Canada
9
McGill University Health Centre, Montreal, QC, Canada
10
Princess Margaret Cancer Centre, Toronto, ON, Canada
11
Bristol–Myers Squibb, Montreal, QC, Canada
12
Cross Cancer Institute, Edmonton, AB, Canada
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2018, 25(6), 384-392; https://doi.org/10.3747/co.25.4287
Submission received: 2 September 2018 / Revised: 13 October 2018 / Accepted: 7 November 2018 / Published: 1 December 2018

Abstract

Background: Nivolumab was the first immuno-oncology agent available for the treatment of lung cancer in Canada. In the present study, we evaluated the real-world benefit of nivolumab in Canadian patients with lung cancer. Methods: Patients included in the cohort were identified from a registry of patients treated through expanded access to nivolumab before and after Health Canada approval. Demographics were collected from the application forms. Outcome data for the duration of treatment and survival were collected retrospectively. Results: In contrast to the randomized clinical trial populations, our study cohort included patients who were older (median age: 66 years; range: 36–92 years) and who had an Eastern Cooperative Oncology Group performance status of 2 (8.9%). Despite the poorer-prognosis cohort, median overall survival was 12.0 months, which is comparable to the survival demonstrated in the randomized phase iii trials of nivolumab in lung cancer. Median time to treatment discontinuation was 3.45 months and was similar for all patient subgroups, including poorer-prognosis groups such as those with a performance status of 2, those 75 years of age and older, and those with brain metastases. Conclusions: Nivolumab given in a real-world clinical setting was associated with results similar to those reported in the phase iii clinical trial setting.
Keywords: Nivolumab; non-small-cell lung cancer; real-world data; duration of treatment; overall survival Nivolumab; non-small-cell lung cancer; real-world data; duration of treatment; overall survival

Share and Cite

MDPI and ACS Style

Juergens, R.A.; Mariano, C.; Jolivet, J.; Finn, N.; Rothenstein, J.; Reaume, M.N.; Faghih, A.; Labbé, C.; Owen, S.; Shepherd, F.A.; et al. Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort. Curr. Oncol. 2018, 25, 384-392. https://doi.org/10.3747/co.25.4287

AMA Style

Juergens RA, Mariano C, Jolivet J, Finn N, Rothenstein J, Reaume MN, Faghih A, Labbé C, Owen S, Shepherd FA, et al. Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort. Current Oncology. 2018; 25(6):384-392. https://doi.org/10.3747/co.25.4287

Chicago/Turabian Style

Juergens, R.A., C. Mariano, J. Jolivet, N. Finn, J. Rothenstein, M.N. Reaume, A. Faghih, C. Labbé, S. Owen, F.A. Shepherd, and et al. 2018. "Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort" Current Oncology 25, no. 6: 384-392. https://doi.org/10.3747/co.25.4287

APA Style

Juergens, R. A., Mariano, C., Jolivet, J., Finn, N., Rothenstein, J., Reaume, M. N., Faghih, A., Labbé, C., Owen, S., Shepherd, F. A., Villeneuve, J., Romeyer, F., Pettersson, F., & Butts, C. (2018). Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort. Current Oncology, 25(6), 384-392. https://doi.org/10.3747/co.25.4287

Article Metrics

Back to TopTop